Sac-TMT in Salivary Gland Cancers
Run by Latin American Cooperative Oncology Group · NCT07928193 · Data updated 2026-11-12
Not yet open. This study is not taking new participants. Its registered completion date is 2030-04.
This is a Phase 2, open-label, non-randomized, parallel, two-cohort study evaluating the efficacy and safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) monotherapy in patients with advanced, recurrent, or metastatic salivary gland carcinomas who have received no more than 3 prior non-curative systemic treatment regimens. The study evaluates the activity of Sac-TMT separately in two independent cohorts based on tumor histology: Cohort 1 for Adenoid Cystic Carcinoma (ACC) and Cohort 2 for Non-Adenoid Cystic Carcinoma (non-ACC).
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 64 (estimated) |
| Sponsor | Latin American Cooperative Oncology Group Academic / other |
| Drugs / interventions | Sacituzumab Tirumotecan (Sac-TMT) |
| Locations | 15 sites (Brazil) |
| Trial ID | NCT07928193 on ClinicalTrials.gov |
What this trial studies
Malignant salivary gland neoplasms are rare and heterogeneous malignancies with limited systemic treatment options and no widely established standard-of-care in advanced settings. Trophoblast cell surface antigen 2 (TROP-2) is broadly expressed in epithelial salivary gland carcinomas, making it a promising therapeutic target. Sacituzumab tirumotecan (Sac-TMT / MK-2870) is an antibody-drug conjugate (ADC) targeting TROP-2 coupled with a topoisomerase 1 inhibitor payload (KL610023). This study aims to evaluate the clinical activity, safety, and patient-reported outcomes of Sac-TMT in two parallel, non-comparative cohorts: Cohort 1: Patients with advanced/metastatic Adenoid Cystic Carcinoma (ACC). Cohort 2: Patients with advanced/metastatic Non-Adenoid Cystic Carcinoma (non-ACC). Participants receive Sac-TMT at a dose of 4 mg/kg via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle for up to 12 cycles (approximately 1 year), or until disease progression, unacceptable toxicity, or withdrawal of consent. The primary objective is to evaluate the Objective Response Rate (ORR) according to RECIST 1.1 in each cohort. Secondary objectives include assessment of ORR by Independent Central Review (ORR-ICR), Disease Control Rate (DCR), Duration of Response (DoR), Progression-Free Survival (PFS), 6- and 12-month PFS, Overall Survival (OS), safety and tolerability, compliance, post-progression therapies, and Patient-Reported Outcomes (EORTC QLQ-C30 and EORTC QLQ-H\&N43). Exp…
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Provided written informed consent for the study (or prescreening phase, as applicable). 2. Histologically- or cytologically confirmed diagnosis of malignant salivary gland neoplasm (assessed by central pathology): * Cohort 1: Adenoid cystic carcinoma (ACC) of the salivary gland. * Cohort 2: Non-adenoid cystic carcinoma (non-ACC) of the salivary gland. 3. Advanced disease, defined as locally advanced or recurrent disease not amenable to curative treatment, and/or metastatic disease. 4. Documented disease progression within 6 months prior to enrollment. 5. Received no more than 3 prior lines of non-curative intent systemic treatment regimens. Note: Patients with salivary duct carcinoma must have been tested for HER2 status; if HER2 positive (IHC 3+ or gene amplified), prior HER2-targeted therapy is required. 6. Measurable disease as defined by RECIST v1.1. 7. Aged 18 years or older at the time of signing informed consent. 8. ECOG Performance Status of 0 or 1. 9. Adequate organ function within 14 days prior to treatment initiation: * Absolute Neutrophil Count (ANC) \>= 1,500/uL; * Platelets \>= 100,000/uL; * Hemoglobin \>= 9.0 g/dL (without transfusion or growth factor support within 2 weeks); * Measured or calculated creatinine clearance \>= 30 mL/min; * Total bilirubin \<= 1.5 x ULN (or direct bilirubin \< ULN for total bilirubin \> 1.5 x ULN); * AST and ALT \<= 2.5 x ULN (\<= 5 x ULN if liver metastases present); * Serum albumin \>= 3.0 g/dL (without albumin transfusion within 72 hours); * INR/PT/aPTT \<= 1.5 x ULN (unless receiving therapeutic anticoagulation). 10. Provision of archival FFPE tumor tissue sample or fresh biopsy. 11. Recovery from adverse events due to prior anticancer therapies to Grade \<= 1 or baseline. 12. Participants with treated HIV, HBV, or HCV are eligible if meeting protocol-specified antiviral stability and disease control parameters. 13. Adherence to protocol-specified contraceptive requirements for male participants and participants of childbearing potential. Exclusion Criteria: 1. History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing. 2. Uncontrolled or significant cardiovascular or cerebrovascular disease within 6 months prior to first dose (e.g., NYHA Class III/IV heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, QTcF \> 480 ms). 3. Prior treatment with a TROP2-targeted ADC or a topoisomerase 1 inhibitor-containing ADC. 4. Systemic anticancer therapy within 2 weeks before the first dose of study intervention. 5. Radiotherapy within 7 days before the first dose (except \<= 10 fractions of palliative radiotherapy for non-CNS disease). 6. Administration of a live or live-attenuated vaccine within 30 days before the first dose. 7. Current use of strong CYP3A4 inducers or inhibitors requiring a 2-week washout prior to enrollment. 8. Concurrent enrollment in another therapeutic clinical trial. 9. Receipt of an investigational agent or device within 4 weeks before the first dose. 10. History of additional active malignancy within the past 3 years (except adequately treated non-melanoma skin cancer, carcinoma in situ, or low-risk prostate cancer). 11. Active, untreated, or unstable CNS metastases and/or carcinomatous meningitis. 12. Active infection requiring systemic therapy. 13. Severe hypersensitivity (Grade \>= 3) to study intervention or its excipients. 14. Major surgery or significant traumatic injury within 4 weeks before the first dose. 15. History of noninfectious pneumonitis/ILD requiring steroids or current clinically meaningful pneumonitis/ILD.
Where it's running
-
CRIO - Centro Regional Integrado de Oncologia
Fortaleza, Ceará, Brazil -
Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel (Oncoclínicas)
Salvador, Estado de Bahia, Brazil -
CETTRO - Centro de Câncer de Brasília (Onco Vida - Oncoclínicas)
Brasília, Federal District, Brazil -
INCA - Instituto Nacional de Câncer
Rio de Janeiro, INCA - Instituto Nacional de Câncer, Brazil -
Oncocentro de Minas Gerais (Oncoclínicas)
Belo Horizonte, Minas Gerais, Brazil -
HCL - Hospital do Câncer de Londrina
Londrina, Paraná, Brazil
Show 9 more locations
-
CTTB - Centro de Tratamento de Tumores Botafogo (Oncoclínicas)
Rio de Janeiro, Rio de Janeiro, Brazil -
Liga Norte Riograndense Contra o Câncer
Natal, Rio Grande do Norte, Brazil -
ISCMPA - Santa Casa de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil -
ANIMI - Unidade de Tratamento Oncológico
Lages, Santa Catarina, Brazil -
Hospital de Amor de Barretos
Barretos, São Paulo, Brazil -
Universidade Estadual de Campinas (UNICAMP)
Campinas, São Paulo, Brazil -
ICESP - Instituto do Câncer do Estado de São Paulo
São Paulo, São Paulo, Brazil -
A.C. Camargo Cancer Center
São Paulo, São Paulo, Brazil -
CPO - Centro Paulista de Oncologia (Oncoclínicas)
São Paulo, São Paulo, Brazil
Study contacts
- Principal investigator: William Nassib William Junior — CPO - Centro Paulista de Oncologia (Oncoclínicas)
- Study coordinator: Project Manager
- Email: lacog1824@lacog.group
- Phone: +55 (51) 3384.5334
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.